A Study of Pyridostigmine in Postural Tachycardia Syndrome
NCT00409435
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Postural Tachycardia Syndrome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 15 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- March 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.